Company Forte Biosciences
Stocks
FBRX
US34962G2084
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-26 EDT
|
5-day change | 1st Jan Change | ||
| 76.99 USD | +0.03% |
|
+0.09% | +182.32% |
| 08-27 | Argenx SE completed the acquisition of Forte Biosciences, Inc.. | CI |
| 08-27 | Argenx Completes Acquisition of Forte Biosciences | MT |
Business description: Forte Biosciences
Number of employees: 23
Sales by Activity: Forte Biosciences
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Geographical breakdown of sales: Forte Biosciences
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Executive Committee: Forte Biosciences
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Wagner
CEO | Chief Executive Officer | 55 | 2017-12-31 |
Anthony Riley
DFI | Director of Finance/CFO | 59 | 2020-02-29 |
| Chief Operating Officer | - | 2020-09-30 | |
Steven Ruhl
CTO | Chief Tech/Sci/R&D Officer | - | 2021-10-31 |
Composition of the Board of Directors: Forte Biosciences
| Director | Title | Age | Since |
|---|---|---|---|
Paul Wagner
CHM | Chairman | 55 | - |
Steven Kornfeld
BRD | Director/Board Member | 58 | 2020-05-31 |
Barbara Finck
BRD | Director/Board Member | 79 | 2022-03-15 |
| Director/Board Member | 67 | 2022-05-11 | |
Scott Brun
BRD | Director/Board Member | 41 | 2022-11-09 |
David Gryska
BRD | Director/Board Member | 70 | 2023-01-09 |
Richard Vincent
BRD | Director/Board Member | 63 | 2024-09-16 |
Shiv S. Kapoor
BRD | Director/Board Member | 51 | 2024-09-16 |
Company details: Forte Biosciences
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.09% | +599.91% | +266.75% | 1.94B | |
| -1.59% | -3.35% | +52.37% | +93.70% | 69.54B | |
| -1.34% | -0.75% | +48.21% | +91.86% | 64.97B | |
| +0.30% | -0.69% | +52.56% | +10.23% | 26.51B | |
| -2.35% | -5.75% | -12.90% | +448.54% | 25.89B | |
| -8.37% | -12.43% | +2.08% | -16.71% | 25.64B | |
| -0.96% | +10.36% | +283.06% | +436.50% | 20.22B | |
| -0.51% | +0.23% | +35.77% | -18.70% | 19.98B | |
| -1.91% | -4.37% | +13.28% | +535.19% | 15.69B | |
| -1.47% | +0.68% | +45.51% | +143.08% | 13.49B | |
| Average | -1.82% | -1.72% | +111.98% | +199.04% | 28.39B | |
| Weighted average by Cap. | -1.92% | -1.49% | +57.46% | +152.30% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- FBRX Stock
- Company Forte Biosciences
Select your edition
All financial news and data tailored to specific country editions
